{"schema_version":"secwatch.filing_event.v1","accession":"0001999480-24-000008","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.428504+00:00","generated_at":"2026-06-04T10:37:29.965930+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alto Neuroscience FY2023 net loss $36.3M; cash ~$210M post-IPO; Phase 2b MDD studies on track","bullets":["Net loss $36.3M in FY2023 (vs $27.7M in 2022); R&D spend $30.3M, G&A $7.5M.","Cash $82.5M at Dec 31, 2023; post-IPO net proceeds ~$133M, cash ~$210M as of Feb 29, 2024.","ALTO-100 Phase 2b MDD enrollment ongoing; topline data 2H 2024. ALTO-300 Phase 2b data 1H 2025.","Appointed Drs. Maha Radhakrishnan (ex-Biogen CMO) and Husseini Manji (ex-J&J) to board.","CIRM approved $15M grant for ALTO-100 Phase 2b in bipolar depression; initiation planned 2024 subject to terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001999480-24-000008","json":"https://secwatch.observer/filing/0001999480-24-000008.json","markdown":"https://secwatch.observer/filing/0001999480-24-000008.md","text":"https://secwatch.observer/filing/0001999480-24-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000199948024000008/0001999480-24-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000199948024000008/alto-form8xk.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:37:29.965930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c3f8ea7c88fa774fa71d3617b523552844f623a8","claim":"Alto Neuroscience, Inc. reported financial results for full year ended December 31, 2023.","evidence_excerpt":"On March 21, 2024, Alto Neuroscience, Inc. (the \"Company\") reported financial results for the full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948024000008/0001999480-24-000008-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}